GetTopicDetailResponse(id=318915509d6, topicName=ritonavir, introduction=ritonavir, content=null, image=null, comments=3, allHits=711, url=https://h5.medsci.cn/topic?id=15509, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=3451, tagList=[TagDto(tagId=3451, tagName=ritonavir)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1793391, encodeId=f90d1e93391de, content=<a href='/topic/show?id=318915509d6' target=_blank style='color:#2F92EE;'>#ritonavir#</a>, objectTitle=武漢金銀譚醫(yī)院的臨床研究證實(shí)，lopinavir-ritonavir抗HIV組合可減輕新冠COVID-19患者癥狀, objectType=article, longId=191735, objectId=0487191e35a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0487191e35a3, replyNumber=0, likeNumber=68, createdTime=2021-01-03, rootId=0, userName=41514487@qq.com, userId=c6a52500178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0487191e35a3, moduleTitle=武漢金銀譚醫(yī)院的臨床研究證實(shí)，lopinavir-ritonavir抗HIV組合可減輕新冠COVID-19患者癥狀, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=0487191e35a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793389, encodeId=61261e93389f8, content=<a href='/topic/show?id=318915509d6' target=_blank style='color:#2F92EE;'>#ritonavir#</a>, objectTitle=J Viral Hepat：采用Paritaprevir/Ombitasvir/Ritonavir, Dasabuvir和Ribavirin等藥物治療HBV和H, objectType=article, longId=129423, objectId=33a2129423ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33a2129423ba, replyNumber=0, likeNumber=74, createdTime=2018-10-21, rootId=0, userName=41514487@qq.com, userId=c6a52500178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33a2129423ba, moduleTitle=J Viral Hepat：采用Paritaprevir/Ombitasvir/Ritonavir, Dasabuvir和Ribavirin等藥物治療HBV和H, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=33a2129423ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1793390, encodeId=19571e93390f4, content=<a href='/topic/show?id=318915509d6' target=_blank style='color:#2F92EE;'>#ritonavir#</a>, objectTitle=Eiger制藥宣布首例患者入組聚乙二醇化干擾素聯(lián)合Ritonavir-Boosted Lonafarnib的II期LIFT研究, objectType=article, longId=146130, objectId=8c0f14613063, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c0f14613063, replyNumber=0, likeNumber=73, createdTime=2018-10-26, rootId=0, userName=41514487@qq.com, userId=c6a52500178, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c0f14613063, moduleTitle=Eiger制藥宣布首例患者入組聚乙二醇化干擾素聯(lián)合Ritonavir-Boosted Lonafarnib的II期LIFT研究, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=8c0f14613063)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
